Original Research
This article aims to demonstrate the real-life effectiveness of the fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen by comparing it with traditional chemotherapy regimens and aims to discover its strengths and weaknesses.
Review
This review summarizes the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.
